Skip to main content

Table 1 Demographic and clinical differences among study cohorts with RX coverage

From: Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States

 

AATD-COPD Cohort (cases)

non-AATD-COPD Cohort (controls)

P valuec

N = 749

N = 5,391

No. of patients

(Column %) / [median]

No. of patients

(Column %) / [median]

Age, mean (SD)

57.10 (11.84)

[57]

52.13 (8.45)

[53]

< 0.001

Age categories, n (%)

    

< 0.001

 30 - 39

51

(7)

453

(8)

 

 40 - 49

151

(20)

1,445

(27)

 

 50 - 59

242

(32)

2,382

(44)

 

 60 - 64

107

(14)

885

(16)

 

 >=65

198

(26)

226

(4)

 

Gender, n (%)

    

0.361

 Male

345

(46)

2,579

(48)

 

 Female

404

(54)

2,812

(52)

 

Race/Ethnicitya, n (%)

    

0.146

 White

625

(83)

4,607

(85)

 

 African American

42

(6)

238

(4)

 

 Hispanic

32

(4)

276

(5)

 

 Unknown

45

(6)

242

(4)

 
     

0.014

Census region, n (%)

 Northeast

89

(12)

475

(9)

 

 Midwest

241

(32)

1,756

(33)

 

 South

304

(41)

2,418

(45)

 

 West

115

(15)

742

(14)

 

Charlson Comorbidity Scorea, n (%)

    

< 0.001

 1

433

(58)

3,680

(68)

 

 2

125

(17)

783

(15)

 

 3

76

(10)

470

(9)

 

 4

42

(6)

191

(4)

 

  ≥5

73

(10)

267

(5)

 
  1. aMissing race/ethnicity was replaced using multinomial logistic regression
  2. bQuan's Enhanced Charlson Comorbidity Score calculated within 365 days before (including) the index
  3. cCalculated with the use of two-sample Mann-Whitney Test for mean age, and chi-square test for categorical variables
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172